Hims Launches Generic Version of Novo Nordisk's Semaglutide in Canada

Hims & Hers Health (HIMS) has launched generic versions of Novo Nordisk’s semaglutide through its telehealth platform in Canada. The move could impact the market for GLP-1 therapies, particularly as semaglutide is a key product marketed under brands like Ozempic and Wegovy.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · May 21, 2026, 13:29 UTC

Hims Launches Generic Version of Novo Nordisk's Semaglutide in Canada

Tickers: $HIMS $NVO

Topics: generic drugs GLP-1 therapy semaglutide telehealth

Read the full article at Seeking Alpha

More World news

Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC